Illuminating the immune interface to develop new cancer therapies
The Enara Bio™ purpose
Shining a light on Dark Antigen™ and T-cell biology to enable people to live free from the shadow of cancer.
Enara Bio is exploring the hidden depths of cancer biology to discover and characterize novel immunotherapy targets, such as Dark Antigens derived from the genomic dark matter or cancer-specific antigens presented by MR1.
To achieve our mission, we have built a differentiated technology platform integrating bioinformatics, immunopeptidomics, metabolomics and immunology that enables us to interrogate both sides of the T-cell/cancer cell interface. Our growing team has the depth of expertise and breadth of experience to advance this exciting area of immuno-oncology for the benefit of broad groups of cancer patients and their families.
Read more about usOur team
We have established a core team of scientists, entrepreneurs and industry veterans to drive our research, development and clinical success.
View team
Kevin Pojasek
President and Chief Executive Officer
Joseph Dukes
Vice President, Translational Science
David Watson
Chief Operating Officer
Latest News
-
Enara Bio to present progress in Dark Antigen™ research at upcoming Neoantigen-Based Therapies Summit
Enara Bio, a biotechnology company leveraging its proprietary T-cell/T-cell receptor (TCR) discovery and Dark Antigen™ platforms to deliver targeted cancer immunotherapies, will present at the 5th Neoantigen Based Therapies Summit on November 5.
-
Ervaxx rebrands as Enara Bio to reflect a broader emphasis on the discovery and development of novel TCR-based cancer immunotherapies
This new name reflects the company’s expanded product discovery and development strategy beyond its initial focus on endogenous retroviral (ERV) antigens for the development of cancer vaccines (hence “Ervaxx”).
-
Ervaxx and Cardiff University enter collaboration to develop novel
T-cell and T-cell receptor-based immunotherapeutics targeting
Dark Antigens™
Collaboration also focuses on exciting research published earlier this week in Nature Immunology identifying MR1 as a target for novel anti-cancer immunotherapies
